- Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market.
- A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was originally expected to initiate in 2020 is primarily to blame.
- With 100% disease free survival ("DFS") in a Phase 2b study that concluded in 2018, the recent insider buying merited closer examination.
- A full investment analysis follows in the paragraphs below.
For further details see:
Greenwich LifeSciences: A First Look